Bilimsel yayın · 2016
Using Interferon Alfa Before Tyrosine Kinase Inhibitors May Increase Survival in Patients With Metastatic Renal Cell Carcinoma: A Turkish Oncology Group (TOG) Study
Clinical Genitourinary Cancer, 2016
Mehmet Artaç, Hasan Şenol Coşkun, Levent Korkmaz, Murat Koçer, Nazım Serdar Turhal, Hüseyin Engin, İsa Dede, Semra Paydaş, Berna Öksüzoğlu, Hakan Bozcuk, Ahmet Demirkazık
Özet
Makalenin özgün dilinde (İngilizce).
Renal cell carcinoma (RCC) accounts for approximately 2% of all cancers.1 On admission, one-third of patients with RCC are at the metastatic stage.2 Chemotherapy resistance is very high in patients with RCC.3 Only a limited subset of patients ( 20%) benefit from cytokine therapy.4-7 It has been shown that the median progressionfree survival (PFS) was 4.7 months for patients with metastatic RCC who received interferon alfa as a first-line treatment …